CERC CERECOR INC

Cerecor Appoints Gilla Kaplan, Ph.D., to the Board of Directors

Cerecor Appoints Gilla Kaplan, Ph.D., to the Board of Directors
EN
12/10/2020

Underlying

CERCCERECOR INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CERECOR INC

 PRESS RELEASE
Free
CERC CERECOR INC

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Second Annual Healthcare Innovation ConferenceFireside ChatNovember 10, 2025, at 4:00 pm ET Stifel 2025 Healthcare ConferenceFireside ChatNovember 12, 2025, at 2:40 pm ET TD Cowen 1st Immunology & Inflamm...

November 3, 2025 1 EN
 PRESS RELEASE
Free
CERC CERECOR INC

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS...

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company has completed enrollment in its Phase 2 LOTUS trial of AVTX-009 in adults with hidradenitis suppurativa (HS). The LOTUS trial exceeded target enrollment of 222 patients with approximately 250 patients enro...

October 29, 2025 1 EN
 PRESS RELEASE
Free
CERC CERECOR INC

Avalo Therapeutics Expands Leadership Team with Key Appointments in Bu...

Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. “We are delighted to welcome Taylor and Ashley to Aval...

October 1, 2025 1 EN
 PRESS RELEASE
Free
CERC CERECOR INC

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Cantor Global Healthcare ConferenceFireside ChatSeptember 3, 2025, at 2:10 pm ET H.C.Wainwright 27th Annual Global Investment ConferencePresentationSeptember 9, 2025, at 2:30 pm ET Stifel 2025 Virtual Immunology and...

August 27, 2025 1 EN
 PRESS RELEASE
Free
CERC CERECOR INC

Avalo Reports Second Quarter 2025 Financial Results and Recent Busines...

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of approximately $113 million as of June 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, t...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch